newsfilter
← Latest News
PR Newswire·

IceCure Medical Receives Regulatory Approval to Market ProSense® in China

  • IceCure Medical Ltd. (NASDAQ: ICCM) received Class III medical device approval from China's National Medical Products Administration (NMPA) for its ProSense® system & associated cryoprobes.
  • The approval enables the commercialization of IceCure's flagship cryoablation technology in China.
  • CEO Eyal Shamir stated the approval strengthens the company's global regulatory position & expands markets for ProSense®.
  • IceCure specializes in liquid-nitrogen-based cryoablation therapy for tumors in breast, kidney, bone, & lung cancer.
  • The company's ProSense® system is currently marketed globally in the U.S., Europe, & Asia.
  • The press release includes standard forward-looking statements & risk factors regarding regulatory developments, funding, & market stability.